MSL
NKTR icon

Mackay Shields LLC’s Nektar Therapeutics NKTR Stock Holding History

Mackay Shields LLC’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,743
Closed -$931K – 1467
2019
Q2 		$931K Buy
1,743
+63
+4% +$31.6K 0.01% 1146
2019
Q1 		$847K Sell
1,680
-76
-4% -$45K 0.01% 1047
2018
Q4 		$866K Sell
1,756
-412
-19% -$249K 0.01% 988
2018
Q3 		$1.98M Buy
2,168
+430
+25% +$367K 0.02% 708
2018
Q2 		$1.27M Sell
1,738
-2,397
-58% -$2.76M 0.01% 893
2018
Q1 		$6.59M Buy
+4,135
New +$5.33M 0.04% 444

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mackay Shields LLC's NKTR Position: Q3 2019 in Review

Mackay Shields LLC sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 1,743 shares — an estimated $931K sold.

Mackay Shields LLC first reported a position in NKTR in Q1 2018 and held it in 6 quarters. The position peaked at $6.59M in Q1 2018. 287 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Mackay Shields LLC reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Mackay Shields LLC sold 1,743 Nektar Therapeutics shares in Q3 2019, an estimated $931K.
  • Mackay Shields LLC first reported a position in Nektar Therapeutics in Q1 2018 and held it in 6 quarters.
  • Mackay Shields LLC's Nektar Therapeutics position peaked at $6.59M in Q1 2018.
  • 287 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Mackay Shields LLC's 13F filing for Q3 2019, filed 1 Nov 2019.